SynthesisBMC cancer2025
Combination of immunotherapy and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer: a meta-analysis of phase 3 trials.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- COVID-19 vaccination and clinical outcomes of immune checkpoint inhibitors therapy in cancer patients: a meta-analysis of real-world studies.Frontiers in immunology · 2026Pooled it
- Current status and targeted therapies in endometrial cancer: Molecular classification-driven treatment strategies (Review).Oncology letters · 2026Review
- Key Tumor Responsive ZIF-8 Nanocarriers for Effective Anti-Cancer Therapeutics.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe integration of immunotherapy with chemotherapy (CT) has emerged as a major focus of clinical research in recent years for patients with advanced or recurrent endometrial cancer (EC). Recent phase 3 randomized controlled trials (RCTs) have reported heterogeneous outcomes, prompting ongoing debate within the oncology community. This study aimed to evaluate the efficacy and safety of this combined approach through a meta-analysis of phase 3 RCTs.
methodsA systematic literature search identified phase 3 RCTs comparing first-line immunotherapy plus CT versus CT alone in advanced or recurrent EC. Meta-analyses were performed to pool hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS), odds ratios (ORs) for objective response rate (ORR), and relative risks (RRs) for adverse events (AEs).
resultsFour phase 3 RCTs (n = 2,334) met eligibility criteria. The combination therapy significantly improved PFS (HR, 0.60; 95% CI, 0.47–0.78), OS (HR, 0.75; 95% CI, 0.65–0.87), and ORR (OR, 1.42; 95% CI, 1.17–1.73) compared to CT alone. While a modest increase in grade 3–5 AEs (RR, 1.11; 95% CI, 1.03–1.20) was observed with combination therapy, there was no significant rise in serious AEs. Subgroup analyses revealed enhanced survival benefits in patients with mismatch repair-deficient (dMMR) tumors, PD-L1-positive tumors, and recurrent disease.
conclusionThis meta-analysis demonstrates that combining immunotherapy with CT as first-line treatment for advanced or recurrent EC offers superior efficacy over CT alone while maintaining a comparable toxicity profile. Notably, greater benefits were observed in dMMR, PD-L1-positive, and recurrent disease subgroups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.